MarketClaims
Sign in
Start free, 10 analysesSign in

The MarketClaims Brief · Published research

What will the FDA's decision be on Ivonescimab by Summit Therapeutics in 2026? (a full approval or an accelerated approval)

30 dated claims from 7 publishers are collected below, each with its source. 6 point toward YES and 0 against it; the rest are context. The research behind this brief is dated 5 November 2026. No direction or probability is published here: the claims and their sources are the brief.

Macro brief. Evidence collected, research dated and published .

This is an older research snapshot. It may miss subsequent developments.

What the evidence does

6
Toward yes
0
Against yes
24
Context

7 publishers26 Oct to 5 Nov 2026Evidence collected

How this market settles

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time. It was developed by Akeso and is being commercialized outside China by Summit Therapeutics. By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time. This market and these products have not been endorsed by any aforementioned brands or its affiliates. Any references to the brand, or any associated marks are descriptive only and do not indicate an endorsement of this product or any affiliation between the brand or its affiliates and Kalshi.

What could still go wrong

  • No official resolution source specified by the market.

Evidence you can inspect These labels describe how a claim relates to the question. They are not recommendations or independent votes.

Evidence supporting YES 6 claims

  • Toward yes

    Summit Therapeutics Inc. is accelerating the global development of ivonescimab, its investigational bispecific cancer antibody

    PharmaDeviceNews published
  • Source publicationPharmaDeviceNewspublished
    Toward yes

    AstraZeneca PLC made a $2 billion strategic equity investment in Summit Therapeutics Inc. on October 5, 2026

    PharmaDeviceNews published
  • Source publicationPharmaDeviceNewspublished
    Toward yes

    The United States Food and Drug Administration (FDA) had a target action date of November 14, 2026, for ivonescimab combined with chemotherapy in previously treated epidermal growth factor receptor-mutated non-small cell lung cancer

    PharmaDeviceNews published
  • Source publicationPharmaDeviceNewspublished
    Toward yes

    The global Phase 3 HARMONi trial demonstrated a statistically significant improvement in progression-free survival for ivonescimab

    PharmaDeviceNews published
  • Toward yes

    Summit Therapeutics has secured positive data in all five Phase 3 clinical trials of ivonescimab announced to date, and demonstrated a statistically significant improvement in overall survival (OS) compared to the standard immuno-oncology drug 'Keytruda' (pembrolizumab) in patients with PD-L1 positive non-small cell lung cancer at the World Conference on Lung Cancer (WCLC 2026) in September

    머니투데이 published
  • Source publicationNaturepublished
    Toward yes

    In the phase 2 trial, MPR rates were 60.0% in the ivonescimab monotherapy cohort and 70.1% in the ivonescimab plus chemotherapy cohort, meeting the primary endpoint's success criterion

    Nature published

Evidence challenging YES 0 claims

No claims in this category. Absence here is a coverage limit, not a finding.

Context 24 claims

  • Source publicationPharmaDeviceNewspublished
    Context

    The FDA considers statistically significant survival evidence necessary for approval of ivonescimab in the proposed setting

    PharmaDeviceNews published
  • Source publicationPharmaDeviceNewspublished
    Context

    Summit Therapeutics Inc. ended September 2026 with $629.8 million in cash, cash equivalents, and short-term investments before receiving AstraZeneca's investment

    PharmaDeviceNews published
  • Source publicationPharmaDeviceNewspublished
    Context

    Summit Therapeutics Inc. reported a third-quarter 2026 net loss of $208.4 million

    PharmaDeviceNews published
  • Source publicationPharmaDeviceNewspublished
    Context

    The original overall-survival analysis of the HARMONi trial did not meet the prespecified statistical threshold for approval

    PharmaDeviceNews published
  • Source publicationRTTNewspublished
    Context

    Summit Therapeutics Inc. is evaluating ivonescimab, an investigational PD-1/VEGF bispecific antibody, for multiple solid tumours

    RTTNews published
  • Source publicationNaturepublished
    Context

    Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, was evaluated in a phase 2 clinical trial for resectable NSCLC, either as monotherapy or in combination with chemotherapy

    Nature published
  • Source publicationRTTNewspublished
    Context

    Allen Yang, MD, PhD, Chief Research and Development Strategy Officer of Summit, stated, "We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab

    RTTNews published
  • Source publicationRTTNewspublished
    Context

    Lunit Inc. and Summit Therapeutics Inc. have entered into a research agreement to evaluate Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumour microenvironment analysis

    RTTNews published
  • Source publicationRTTNewspublished
    Context

    The research agreement aims to support Summit's immuno-oncology development programs for ivonescimab

    RTTNews published
  • Source publication조선일보published
    Context

    The agreement between Lunit and Summit Therapeutics aims to develop the next-generation immune anticancer drug 'ivonescimab'

    조선일보 published
  • Source publication인터넷뉴스 한경닷컴published
    Context

    Lunit announced on the 26th that it will collaborate with Nasdaq-listed Summit Therapeutics on AI biomarker research for the development of the next-generation immuno-oncology drug 'ivonescimab'

    인터넷뉴스 한경닷컴 published
  • Source publication인터넷뉴스 한경닷컴published
    Context

    Global pharmaceutical company AstraZeneca recently invested $2 billion (approximately 2.7 trillion won) in Summit Therapeutics and is proceeding with the development of anti-cancer drugs using ivonescimab, making Lunit's technology's application to this new drug research noteworthy

    인터넷뉴스 한경닷컴 published
  • Source publication인터넷뉴스 한경닷컴published
    Context

    Han Seung-yeon, a researcher at NH Investment & Securities, stated, "This collaboration with Lunit is an important first early AI biomarker collaboration case for Summit Therapeutics in developing ivonescimab, and selecting Lunit as a partner confirms the high global trust in SCOPE's technological prowess

    인터넷뉴스 한경닷컴 published
  • Source publication머니투데이published
    Context

    Summit Therapeutics will apply Lunit's AI biomarker platform, 'Lunit Scope IO', to its ivonescimab development program

    머니투데이 published
  • Source publication머니투데이published
    Context

    Lunit, a medical AI company, has partnered with Summit Therapeutics, a US Nasdaq-listed biopharmaceutical company, to collaborate on AI biomarker research for the next-generation immuno-oncology drug 'ivonescimab'

    머니투데이 published
  • Source publicationNaturepublished
    Context

    Perioperative PD-1 or PD-L1 inhibitors combined with chemotherapy have shown improved antitumor efficacy in resectable NSCLC compared to chemotherapy alone

    Nature published
  • Source publicationNaturepublished
    Context

    The CheckMate 816 trial demonstrated that neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response (pCR) in resectable NSCLC patients (24% vs. 2.2%) compared to chemotherapy alone

    Nature published
  • Source publicationNaturepublished
    Context

    Subsequent phase 3 trials like KEYNOTE-671, AEGEAN, Neotorch, CheckMate 77T, and RATIONALE-315 also showed superior pathological response with neoadjuvant immunochemotherapy, with major pathological response (MPR) rates between 30.2% and 56%, and pCR rates between 17.2% and 41%

    Nature published
  • Source publicationNaturepublished
    Context

    The combination of neoadjuvant PD-1/PD-L1 inhibitor plus chemotherapy followed by adjuvant PD-1/PD-L1 inhibitor is now the standard of care according to international guidelines

    Nature published
  • Source publicationNaturepublished
    Context

    Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with about 25% of patients having surgically resectable disease

    Nature published
  • Source publicationNaturepublished
    Context

    Despite surgery being the primary cure for early-stage NSCLC, 30-70% of patients experience postoperative recurrence, often leading to distant metastases and poor survival

    Nature published
  • Source publicationRTTNewspublished
    Context

    The companies intend to determine if AI-powered pathology can aid in biomarker discovery, patient stratification, treatment selection, and understanding responses to ivonescimab-based therapies

    RTTNews published
  • Source publicationmk.co.krpublished
    Context

    Summit Therapeutics plans to use Lunit's AI pathology analysis platform, 'Lunit Scope IO', to analyze the tumor microenvironment and select patient groups expected to have high treatment efficacy

    mk.co.kr published
  • Source publicationmk.co.krpublished
    Context

    Summit Therapeutics is a company that recently announced a strategic equity investment of $2 billion (approximately 2.7 trillion won) from the global pharmaceutical company AstraZeneca

    mk.co.kr published

Who reported it 7 publishers, each setting its own name

  • Nature 8
  • PharmaDeviceNews 8
  • RTTNews 5
  • 머니투데이 3
  • 인터넷뉴스 한경닷컴 3
  • mk.co.kr 2
  • 조선일보 1

What this brief cannot settle

This brief was assembled automatically from a research report that met a published quality bar. No individual review. It rests on 30 claims from 7 publishers; anything not reported in those sources is not represented here. The report recorded 1 resolution risk, listed with this brief.

Since the previous brief

Publication history (1 recorded revisions)
  1. Published · research dated

This is the first published brief for this event. No comparison is available.

More published research